Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication DOI Creative Commons

Ellie Swords,

Breandán N. Kennedy, Valentina Tonelotto

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 1, 2024

Uveal melanoma (UM) is the most common primary intraocular tumour in adults. Local resection, radiation therapy, and enucleation are current first-line, UM treatments. However, regardless of treatment received, around 50% patients will develop metastatic disease within five to 7 years. In largest published series unselected with (mUM), median survival time after diagnosis metastasis was 3.6 months, less than 1% surviving beyond 5 Approved drugs for mUM include systemic tebentafusp-tebn or isolated hepatic perfusion (IHP) melphalan. these only available a subset improve by few highlighting urgent need new Accurately predicting which at high risk metastases also crucial. Researchers developing gene expression signatures create reliable prognostic models aimed improving patient follow-up strategies. this review we discuss evidence supporting ferroptosis, non-apoptotic form cell death, as potential novel target prognosticator UM.

Language: Английский

Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication DOI Creative Commons

Ellie Swords,

Breandán N. Kennedy, Valentina Tonelotto

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 1, 2024

Uveal melanoma (UM) is the most common primary intraocular tumour in adults. Local resection, radiation therapy, and enucleation are current first-line, UM treatments. However, regardless of treatment received, around 50% patients will develop metastatic disease within five to 7 years. In largest published series unselected with (mUM), median survival time after diagnosis metastasis was 3.6 months, less than 1% surviving beyond 5 Approved drugs for mUM include systemic tebentafusp-tebn or isolated hepatic perfusion (IHP) melphalan. these only available a subset improve by few highlighting urgent need new Accurately predicting which at high risk metastases also crucial. Researchers developing gene expression signatures create reliable prognostic models aimed improving patient follow-up strategies. this review we discuss evidence supporting ferroptosis, non-apoptotic form cell death, as potential novel target prognosticator UM.

Language: Английский

Citations

0